BioCryst Pharmaceuticals | BCRX - 应收帐款人



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.85B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


应收帐款人 更改 日
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Chugai Pharma JPY 352.94B 90.17B 2026-03
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
DBV Technologies USD 15.97M 279K 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Incyte USD 1.05B 27.09M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novavax USD 106.45M 72.27M 2025-12
PTC Therapeutics USD 181.62M 21.45M 2025-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03